Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Cost-Effectiveness of CT Perfusion for Selecting Stroke Patients for Thrombolysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Competitive Interactions between Immature Stages of Bactrocera cucurbitae (Coquillett) and Bactrocera tau (Walker) (Diptera: Tephritidae) under Laboratory Conditions.

Neotropical entomology·2016
Same author

β-Arrestin1 inhibits chemotherapy-induced intestinal stem cell apoptosis and mucositis.

Cell death & disease·2016
Same author

Psychological characteristics of and counseling for carriers of structural chromosome abnormalities.

Genetics and molecular research : GMR·2016
Same author

β-Arrestin-2 modulates radiation-induced intestinal crypt progenitor/stem cell injury.

Cell death and differentiation·2016
Same author

Contact force-guided catheter ablation for the treatment of atrial fibrillation: a meta-analysis of randomized, controlled trials.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2016

Related Experiment Video

Updated: Jul 18, 2026

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy.

B Wu1, J M Wu, A Miagkov

  • 1Neuromuscular Research Laboratory, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|March 20, 2001
PubMed
Summary

Genetically engineered antigen-presenting cells (APCs) simultaneously express antigen and Fas ligand (FasL) to eliminate specific T cells. This engineered APC approach shows promise for treating autoimmune diseases.

More Related Videos

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells
13:18

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells

Published on: December 29, 2012

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

Related Experiment Videos

Last Updated: Jul 18, 2026

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells
13:18

Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells

Published on: December 29, 2012

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

Area of Science:

  • Immunology
  • Genetic Engineering
  • Cell Biology

Background:

  • Antigen-presenting cells (APCs) play a crucial role in immune responses.
  • Targeting specific T cells is a potential strategy for autoimmune disease treatment.

Purpose of the Study:

  • To test the hypothesis that APCs engineered to present an antigen (Ag) and express Fas ligand (FasL) can eliminate Ag-specific T cells.
  • To develop a novel strategy for targeted T cell elimination in autoimmune diseases.

Main Methods:

  • APCs were genetically engineered using recombinant vaccinia virus vectors (VVVs).
  • Genes for antigen presentation (hemagglutinin - HA) and FasL were introduced into APCs.
  • A truncated Fas-associated death domain was transferred to protect APCs from FasL-induced apoptosis.
  • Psoralen-UV light treatment attenuated VVVs to prevent viral replication.

Main Results:

  • Engineered APCs successfully expressed the introduced genes.
  • APCs transduced with all three gene constructs specifically killed HA-specific T cells in vitro.
  • Coculture with T cells specific for an unrelated antigen (OVA) showed no significant effect.

Conclusions:

  • Genetically engineered APCs can be developed to specifically target and eliminate antigen-specific T cells.
  • This approach represents a promising novel strategy for the specific treatment of autoimmune diseases.